GATA1 mutations in acute leukemia in children with Down syndrome. 2006

Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
Departamento de Hematologia/Oncologia Pediátrica SES-DF, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.

It has been reported that somatic mutations in the X-linked GATA1 gene are present in hematological clonal disorders in children with Down syndrome (DS). We analyzed retrospective samples of DS children with acute myeloid leukemia, transient leukemia (TL), and myelodysplastic syndrome (MDS) to test whether the specificity of GATA1 mutations can be helpful in distinguishing these hematopoietic disorders. A total of 49 samples were subjected to GATA1 mutation screening by direct sequencing and denaturing polyacrylamide gel electrophoresis (PAGE). Mutations in exon 2 of GATA1 were detected in six of eight DS-AML M7 samples and in four of six DS-TL; no mutation was detected in 13 children with acute lymphoblastic leukemia (DS-ALL), 6 with DS-AML (M0, M2, and M5), 6 with DS-MDS and in 8 DS infants without hematological disorders and 2 children with AML M7 without DS. Blast cells proportion in the sample represented a critical aspect on the sensitivity of mutation detection in GATA1, and a combination of sequence analysis and PAGE is necessary to detect mutations when blast percentage is low. The absence of detected mutations in any of the DS-MDS cases raises the question whether MDS in DS children is an intermediate stage between TL and AML M7, as previously suggested.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D004314 Down Syndrome A chromosome disorder associated either with an extra CHROMOSOME 21 or an effective TRISOMY for chromosome 21. Clinical manifestations include HYPOTONIA, short stature, BRACHYCEPHALY, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, single transverse palmar crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213) Mongolism,Trisomy 21,47,XX,+21,47,XY,+21,Down Syndrome, Partial Trisomy 21,Down's Syndrome,Partial Trisomy 21 Down Syndrome,Trisomy 21, Meiotic Nondisjunction,Trisomy 21, Mitotic Nondisjunction,Trisomy G,Downs Syndrome,Syndrome, Down,Syndrome, Down's
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D050982 GATA1 Transcription Factor A GATA transcription factor that is specifically expressed in hematopoietic lineages and plays an important role in the CELL DIFFERENTIATION of ERYTHROID CELLS and MEGAKARYOCYTES. Eryf1 Erythroid-Specific Transcription Factor,Erythroid Transcription Factor 1,Globin Transcription Factor 1,NF-E1 Erythroid-Specific Transcription Factor,Nuclear Factor-Erythroid 1,Transcription Factor GATA1,Transcription Factor NFE-1,Eryf1 Erythroid Specific Transcription Factor,Factor GATA1, Transcription,GATA1, Transcription Factor,NF E1 Erythroid Specific Transcription Factor,NFE-1, Transcription Factor,Nuclear Factor Erythroid 1,Transcription Factor, GATA1

Related Publications

Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
June 2003, Blood,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
September 2002, Nature genetics,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
August 2014, Medical hypotheses,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
January 2003, Blood cells, molecules & diseases,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
January 2005, Pediatric blood & cancer,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
February 2005, Journal of the National Cancer Institute,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
August 2011, Blood,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
April 2004, Blood,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
March 2007, The Journal of pediatrics,
Isis Quezado Magalhães, and Alessandra Splendore, and Mariana Emerenciano, and Alexandre Figueiredo, and Iris Ferrari, and Maria S Pombo-de-Oliveira
June 2016, Singapore medical journal,
Copied contents to your clipboard!